{"id":44720,"date":"2023-02-01T07:35:51","date_gmt":"2023-02-01T07:35:51","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=44720"},"modified":"2024-07-28T10:37:11","modified_gmt":"2024-07-28T10:37:11","slug":"lenacapavir-approved-in-the-us-for-multidrug-resistant-hiv","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/44720","title":{"rendered":"Lenacapavir approved in the US for multidrug resistant HIV"},"content":{"rendered":"<div>\n<p class=\"HTBsubhead2articletitle\"><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><strong><span lang=\"EN-US\">On 22 December 2022, the US FDA approved the capsid inhibitor lenacapavir for multidrug resistant HIV. [1]<\/span><\/strong><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">Lenacapavir is a long-acting drug given by subcutaneous injection.<\/span><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">It was approved in the EU by the EMA in August 2022, [2]<\/span><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">References<\/span><\/p>\n<ol>\n<li class=\"HTBBODYtext\">Gilead press release Sunlenca (lenacapavir) receives FDA approval as a first-in-class, twice-yearly treatment option for people living with multi-drug resistant HIV. (22 December 2022).<br \/>\n<a href=\"https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2022\/12\/sunlenca-lenacapavir-receives-fda-approval-as-a-firstinclass-twiceyearly-treatment-option-for-people-living-with-multidrug-resistant-hiv\" rel=\"noopener\">https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2022\/12\/sunlenca-lenacapavir-receives-fda-approval-as-a-firstinclass-twiceyearly-treatment-option-for-people-living-with-multidrug-resistant-hiv<\/a><\/li>\n<li class=\"HTBBODYtext\">Lenacapavir approved in the EU and UK to treat multidrug resistant HIV. HTB September 2022.<br \/>\n<a href=\"https:\/\/i-base.info\/htb\/43776\">https:\/\/i-base.info\/htb\/43776<\/a><\/li>\n<\/ol>\n<p>This report was first posted online in December 2022.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base On 22 December 2022, the US FDA approved the capsid inhibitor lenacapavir for multidrug resistant HIV. [1] Lenacapavir is a long-acting drug given by subcutaneous injection. It was approved in the EU by the EMA in &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-44720","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/44720","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=44720"}],"version-history":[{"count":5,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/44720\/revisions"}],"predecessor-version":[{"id":48259,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/44720\/revisions\/48259"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=44720"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=44720"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=44720"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}